Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

TOKYO& BASKING RIDGE, N.J.--(BUSINESS WIRE)-- April 21, 2023 -- Daiichi Sankyo (TSE: 4568) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) of quizartinib in...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news